Sònia Guedan

Grupo de investigación

Inmunoterapias celulares para el cáncer Junior group leader (R3B)

sguedan@recerca.clinic.cat 0000-0002-9605-0760

Publicaciones destacadas

Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?

Autores:
Guedan, S; Luu, M; Ammar, D; Barbao, P; Bonini, C;

(...)

Rodriguez-Madoz, JR; Ruggiero, E; Themeli, M; Hudecek, M; Marchiq, I.

Referencia: Journal For Immunotherapy Of Cancer 2022.
An NK-like CAR T cell transition in CAR T cell dysfunction

Autores:
Good, CR; Aznar, MA; Kuramitsu, S; Samareh, P; Agarwal, S;

(...)

Albelda, SM; Lanier, LL; Young, RM; Berger, SL; June, CH.

Referencia: Cell 2021.
Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer

Autores:
Schettini, F; Barbao, P; Brasó-Maristany, F; Galván, P; Martínez, D;

Paré, L; De Placido, S; Prat, A; Guedan, S.

Referencia: Esmo Open 2021.
Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability

Autores:
Guedan S; Madar A; Casado-Medrano V; Shaw C; Wing A;

Liu F; Young RM; June CH; Posey AD .

Referencia: Journal Of Clinical Investigation 2020.
Engineering and Design of Chimeric Antigen Receptors

Autores:
Guedan S; Calderon H; Posey AD; Maus MV ;

Referencia: Molecular Therapy-Methods & Clinical Development 2019.
Emerging Cellular Therapies for Cancer

Autores:
Guedan S; Ruella M; June CH ;

Referencia: Annual Review Of Immunology 2019.
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation

Autores:
Guedan, Sonia; Posey, Avery D., Jr.; Shaw, Carolyn; Wing, Anna; Da, Tong;

(...)

Lacey, Simon F.; Scholler, John; Keith, Brian; Young, Regina M.; June, Carl H.;.

Referencia: Jci Insight 2018.
Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.

Autores:
Wing A; Fajardo CA; Posey AD; Shaw C; Da T;

Young RM; Alemany R; June CH; Guedan S .

Referencia: Cancer Immunology Research 2018.
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

Autores:
Kawalekar OU; O'Connor RS; Fraietta JA; Guo L; McGettigan SE;

(...)

Keith B; Snyder N; Blair I; Milone MC; June CH.

Referencia: Immunity 2016.
Hyaluronidase Expression by an Oncolytic Adenovirus Enhances Its Intratumoral Spread and Suppresses Tumor Growth

Autores:
Guedan, Sonia; Jose Rojas, Juan; Gros, Alena; Mercade, Elena; Cascallo, Manel;

Alemany, Ramon;.

Referencia: Molecular Therapy 2010.

Proyectos destacados

Fine-tuning T cell networks of exhaustion by synthetic sensors

Investigador/a principal: Sònia Guedan Carrió

Financiador: European Commission

Código: HORIZON-EIC-2021-Pathfinder

Duración: 01/09/2022 - 30/08/2026
Development of enabling technologies for T-cell immunotherapy

Investigador/a principal: Sònia Guedan Carrió

Financiador: Fundación La Caixa

Código: Health Research_2021

Duración: 01/10/2021 - 30/09/2024
T2EVOLVE: Accelerating Development and Improving Access to CAR and TCR-engineered T cell therapy

Investigador/a principal: Sònia Guedan Carrió

Financiador: European Commission

Código: CE_IMI12_18th_2stg

Duración: 01/01/2021 - 31/12/2025
CAR-T cells as drug delivery agents for the treatment of solid tumors

Investigador/a principal: Sònia Guedan Carrió

Financiador: Asociación Española Contra el Cáncer

Código: AECC_Lab20

Duración: 01/12/2020 - 29/02/2024
Chimeric Antigen Receptor (CAR)-modified T cells for the treatment of solid tumours

Investigador/a principal: Sònia Guedan Carrió

Financiador: Agencia Estatal de Investigacion (AEI)

Código: PID2019-109546RA-I00

Duración: 01/06/2020 - 31/05/2023

Sònia Guedan

Grupo de investigación

Publicaciones destacadas

Proyectos destacados

Fine-tuning T cell networks of exhaustion by synthetic sensors

Development of enabling technologies for T-cell immunotherapy

T2EVOLVE: Accelerating Development and Improving Access to CAR and TCR-engineered T cell therapy

CAR-T cells as drug delivery agents for the treatment of solid tumors

Chimeric Antigen Receptor (CAR)-modified T cells for the treatment of solid tumours

Suscríbete a la Newsletter del Clínic